Table 3 Changes in CV risk factors from baseline to last measurement in the pooled cohorts of 8 trials of linagliptin versus total comparators (placebo and active treatment)
Pooled linagliptin | Pooled total comparators | |||
|---|---|---|---|---|
Baseline | Study end | Baseline | Study end | |
HbA1c , mmol/mol | 64 ± 10 | 58 ± 11 | 63 ± 10 | 60 ± 13 |
HbA1c, % | 8.1 ± 0.9 | 7.5 ± 1.0 | 8.0 ± 0.9 | 7.7 ± 1.2 |
Systolic BP, mmHg | 131 ± 15 | 130 ± 15 | 132 ± 15 | 132 ± 15 |
Diastolic BP, mmHg | 79 ± 9 | 78 ± 9 | 79 ± 9 | 79 ± 9 |
Total cholesterol, mmol/L | 4.6 ± 0.6 | 4.6 ± 0.6 | 4.6 ± 0.6 | 4.7 ± 0.6 |
Triglycerides, mmol/L | 2.6 ± 1.8 | 2.5 ± 1.8 | 2.6 ± 1.9 | 2.6 ± 1.9 |
Body weight, kg | 78.9 ± 17.7 | 78.9 ± 17.6 | 81.0 ± 17.4 | 81.6 ± 17.9 |